8-K: Cytek Biosciences Reports Strong Q4, Full-Year 2025 Revenue

Cytek Biosciences announced preliminary unaudited revenue of $62 million for Q4 2025, an 8% year-over-year increase, and $201 million for the full year 2025, signaling accelerated growth.

Summary

• Preliminary unaudited revenue for the full year ended December 31, 2025, is expected to be approximately $201 million.
• Preliminary unaudited revenue for the fourth quarter of 2025 is expected to be approximately $62 million.
• Fourth quarter 2025 revenue represents an 8% growth compared to the fourth quarter of 2024.
• Fourth quarter 2025 revenue represents a 19% growth compared to the third quarter of 2025.
• The fourth quarter revenue growth over the prior year signifies a meaningful acceleration of growth compared to prior quarters in 2025.
• Positive trends observed in the third quarter continued, including strong growth in Services, Reagents, and Asia Pacific instrument revenue.
• Instrument revenue growth improved in the US and EMEA, with a return to positive growth in EMEA instrument sales during the fourth quarter.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the reported acceleration in revenue growth, strong performance across key segments and regions, and management's optimistic outlook for sustainable growth and profitability. The preliminary nature of the results is the only minor cautionary note.

Positives

• Achieved a meaningful acceleration of revenue growth in the fourth quarter of 2025 compared to prior quarters in the same year.
• Reported strong growth in Services, Reagents, and Asia Pacific instrument revenue.
• Experienced an improvement in instrument revenue growth in both the US and EMEA regions.
• Noted a return to positive growth in instrument sales specifically within the EMEA region during the fourth quarter.
• Management believes the company is well positioned to deliver sustainable growth and profitability in the large flow cytometry market.

Negatives

• None explicitly stated, but the preliminary and unaudited nature of the results means they are subject to adjustment upon completion of year-end closing and auditing procedures.

Risks

• Preliminary revenue estimates are subject to adjustments during the completion of year-end closing and auditing procedures.
• Global geopolitical, economic, and market conditions could impact business operations and financial results.
• Ability to manage the impacts of recent and future export controls, licensing requirements, tariffs, and NIH funding policies on the business.
• Challenges in evaluating prospects for future viability and predicting future performance.
• Difficulty in accurately forecasting customer demand and adoption of products.
• Ability to recognize the anticipated benefits of collaborations.
• Dependence on certain sole and single-source suppliers poses supply chain risks.
• Competition in the cell analysis solutions market could affect market share and profitability.
• Market acceptance of current and potential products is crucial for revenue growth.
• Ability to manage the growth and complexity of the organization, maintain relationships with customers and suppliers, and hire and retain key employees.
• Ability to manufacture products in high-quality commercial quantities successfully and consistently to meet demand.
• Ability to increase penetration in existing markets and expand into adjacent markets.
• Ability to secure additional distributors or maintain good relationships with existing distributors.
• Ability to successfully develop and introduce new products.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to continue to stay in compliance with material contractual obligations, applicable laws, and regulations.
• Foreign currency exchange impacts could affect financial results.

Future Outlook

Management believes the company is well positioned to deliver sustainable growth and profitability in the large flow cytometry market, building on the accelerated growth trends observed in the latter half of 2025. The company plans to provide 2026 financial guidance during its earnings call near the end of February 2026.

Management Comments

• "Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025 and reflects a continuation of positive trends we saw emerging in the third quarter."
• "These trends include a continuation of strong growth in Services, Reagents and Asia Pacific instrument revenue and an improvement in instrument revenue growth in the US and EMEA."
• "We were particularly pleased to see a return to positive growth in our instrument sales in EMEA in the fourth quarter."
• "With strong execution across our portfolio, we believe we are well positioned to deliver sustainable growth and profitability in a large flow cytometry market."

Industry Context

Cytek Biosciences operates in the specialized and growing cell analysis solutions market, particularly within flow cytometry. The reported acceleration in revenue growth, especially in key segments like Services, Reagents, and Asia Pacific, along with improved instrument sales in the US and EMEA, suggests the company is effectively navigating market dynamics and potentially gaining share or benefiting from broader industry tailwinds. The return to positive growth in EMEA instrument sales indicates a recovery or strengthening in a significant regional market.

Stakeholder Impact

• Shareholders: The accelerated revenue growth and positive trends are likely to be viewed favorably, potentially leading to increased investor confidence and share price appreciation.
• Employees: Continued growth and profitability could lead to job stability, potential expansion, and opportunities within the company.
• Customers: Strong financial performance supports ongoing investment in product development and service enhancements, benefiting customers through advanced cell analysis solutions.
• Suppliers: Increased demand and production driven by revenue growth could lead to stronger relationships and increased business for suppliers.
• Creditors: Improved financial health and growth prospects enhance the company's creditworthiness.

Next Steps

• Cytek will participate and present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Cytek plans to report full financial results for the fourth quarter and full year ended December 31, 2025, near the end of February 2026.
• The company will provide 2026 financial guidance during its earnings call expected near the end of February 2026.

Key Dates

Recommendation

The preliminary results indicate a significant positive shift in Cytek's growth trajectory, with a 'meaningful acceleration' in Q4 revenue and strong performance across key segments and geographies. The return to positive growth in EMEA instrument sales is particularly encouraging. While these results are unaudited, the strong underlying trends and management's confidence in sustainable growth position the company favorably. Investors seeking exposure to the cell analysis market, especially a company demonstrating renewed momentum, should consider a 'buy' recommendation, with the understanding that full audited results and 2026 guidance will provide further clarity.

Keywords

Cytek Biosciences, CTKB, Revenue, Financial Results, Fourth Quarter 2025, Full Year 2025, Preliminary Results, Cell Analysis, Flow Cytometry, Growth, Healthcare Conference